Our Core Team
StarkAge is driven by a leadership team with a proven track record in ADC innovation, IND-enabling strategy, and first-in-human oncology development.
Combining deep expertise in drug design, CMC, and early clinical execution, including prior experience with DPP4-targeted therapies, the team is uniquely positioned to rapidly advance STX-1 toward the clinic.
Chief Executive Officer
Benjamin Le Calvé,
PhD
Postdoctoral experiences in senescence (Lyon and Montreal)
Expert in development of targeted therapies
Executive President
Florence Lhospice, PharmD, PhD
Co-founder and CDO at Emergence Therapeutics (acquired by Eli Lilly in 2024)
Specialist in ADC development (CMC and regulatory)
Chief Medical Officer
Eric Angevin,
MD, PhD
Oncologist and alliance manager at Gustave Roussy Institute
More than 20 years of experience in early-phase clinical development
Stay tuned
We’re building something new.
While our website is being redesigned, feel free to reach out or leave your details to be notified when we go live.